



EVALUATING BIOPHARMA

Online Networking and Educational Event Series

Unique Insight

Actionable Advice

Convenient Networking

Better Results

2023 Schedule of Events



A DIVISION OF
Cambridge **Healthtech** Institute

EvaluatingBiopharma.com

▲ Previous ▼ Next

[INQUIRE ABOUT SPONSORSHIP](#)

Welcome to Evaluating Biopharma

Why Evaluating Biopharma Events Work So Well

Audience

Online
Interactive Events

Science
is evolving.

Technology
is evolving.

Business
is evolving.

Communication
is evolving.

It's time to evolve your
lead-gen strategy.



Brian Caine
Co-Founder and Managing Director



908-809-0946
bcaine@healthtech.com



Now part of the Cambridge Healthtech Institute (CHI) family of events, Evaluating Biopharma events are single-themed, networking and educational meetings strategically designed to fill the education/communication gap that currently exists between webinars and in-person events.

Evaluating Biopharma's mission is convene industry decision makers and create productive atmospheres where attendees can discuss universal challenges, share experiences, and consider new technologies and solutions to improve process efficiency, accelerate manufacturing, and accelerate success.

Building on content presented at The Bioprocessing Summit and Bioprocessing Summit Europe events, Evaluating Biopharma's 1:1 fireside chat style format provides its expert moderators and presenters the opportunity to "pay it forward" by sharing personal insights, experiences and case studies highlighting how they identified, addressed, and resolved critical bioprocessing challenges.

Two interactive "cocktail-style" networking receptions allow biopharmaceutical leaders with a convenient opportunity to meet, discuss and leverage the expertise presented to make more effective business, process, and strategy decisions.

Partner with Evaluating Biopharma.
Let's change the status-quo. Together.

For information regarding sponsorship, please contact:

Companies A-M

Phillip Zakim-Yacouby
Senior Manager, Business Development
Evaluating Biopharma
a Division of Cambridge Healthtech Institute
Phone: (+1) 617-247-1815
Email: pzakim-yacouby@cambridgeinnovationinstitute.com



Better Format:

Convenient, interactive, well-produced single-themed virtual events focus on discussing and resolving specific bioprocessing challenges.

Better Content:

A real "pay it forward" atmosphere. Our industry veterans present case studies and share personal insights and experiences on how they identified, addressed, and resolved critical bioprocessing challenges related to the event theme.

Better Attendees:

Everyone in the room is connected to the event theme. Everyone is a decision-maker. Attendance is invitation-only and complimentary based on pre-qualification.

Better Networking:

Two cocktail-style networking sessions connect the "walk to the talk" by encouraging attendees, speakers, sponsors to network and interact to truly learn, apply, and change the bioprocessing status quo.

Better Deliverables:


Full attendee contact info/demos so your BD folks can follow up on initial conversations and connect with the folks they missed during networking; pre-event visibility allow you to put a spotlight on your thought leadership; on-site networking; acknowledgement; inclusion in all post event summary articles; advertising in post-event ebooks and newsletters, plus much more.

Companies N-Z

Aimee Croke
Senior Manager, Business Development
Evaluating Biopharma
a Division of Cambridge Healthtech Institute
Phone: (+1) 781-292-0777
Email: acroke@cambridgeinnovationinstitute.com




Speaker Profile



- **Innovators**
(Founders, Chairman, Presidents)
25%
- **Executives**
(CEOs, CCOs, CSOs, COOs, CTOs):
30%
- **Leaders**
(Dept/Business Heads, Principals,
Senior Directors)
45%

Attendee Profile



- **Executives** 18%
- **Supervisors/Directors** 39%
- **Senior Scientists** 31%
- **Managers/Group Leaders/Engineers** 12%


Evaluating Biopharma Events

Delivering uniquely interactive online experiences for attendees and sponsors

Online Interactive Events

Evaluating Biopharma events are purposely designed to complement your existing digital and in-person event strategy. Each event is single-topic focused - which means everyone attending is connected to the theme. All attendees are invited, qualified, and GDPR compliant. The 1:1 conversation format allows industry veterans to share personal experiences, provide advice and “pay it forward” to help today’s leaders make better process and business decisions. Your SMEs are active participants in the events. The two networking sessions are designed so they can chat, connect and meet face to face with attendees.

As a sponsor, you will receive the full demo attendee list for quick post-event follow up. Evaluating Biopharma also publishes summary articles, podcasts and ebooks based on each event to extend your engagement and showcase your expertise to the wider market. Most importantly for you – Evaluating Biopharma events require very little prep work on your part and are priced right!




Live, 1:1 Conversations with Industry Experts

Veteran industry experts “pay it forward” by sharing personal experiences, insight, and advice to help today’s biopharma leaders make better process and business decisions.

Benefits include:

- A real “pay it forward” atmosphere
- Personal insight and advice
- Addressing today’s process and business challenges



Interactive Networking

Two interactive networking sessions provide branding and allow sponsor SMEs to participate, chat and showcase your solutions and expertise

Networking with delegates:

- Work the room - identify and chat with qualified attendees
- Join group conversations
- Set up private 1:1 meetings
- Pre-event attendee list provided
- Full demo attendee list provided post-event

**Online
Interactive Events**

**Ready to Learn More?
Contact Us For More
Information:**

**For General Series
Information**

Brian Caine
Co-Founder and
Managing Director
908-809-0946
bcaine@cambridge
innovationinstitute.com

Companies A-M

Phillip Zakim-Yacouby
Senior Manager, Business
Development
Evaluating Biopharma
Phone: (+1) 617-247-1815
Email: pzakim-yacouby@
cambridgeinnovation
institute.com

Companies N-Z

Aimee Croke
Senior Manager,
Business Development
Evaluating Biopharma
Phone: (+1) 781-292-0777
Email: acroke@cambridge
innovationinstitute.com

In a nutshell – *Evaluating Biopharma* networking events are designed to deliver a better return on your investment. Let’s talk about how your company can leverage Evaluating Biopharma events to: (1) facilitate quality client conversations (without leaving the office); (2) deliver better qualified lead generation; (3) support a truly unique educational event series.

Pre-conference:

- Attendee list provided Monday before event to prioritize and maximize networking opportunities (Includes First Name, Last Name, Title, Department, Company, and Location)
- Dedicated content: thought leadership email to all event attendees and inclusion in social media promotions
- Company logo and link included in all event promotions
- Company logo and link on Evaluating Biopharma homepage and event page(s)
- Event-specific banners for you to promote your participation on social media, website, and in emails

During-conference:

- 3 complimentary registrations for SME/BD personnel
- 5 complimentary VIP client registrations
- Registrations include access and participation in all education and networking sessions
- Opportunity to connect and meet with attendees during networking sessions
- Company logo and link to thought leadership promoted during networking sessions
- Mention and acknowledgement as event sponsor from event host
- Moderator deliverables include: pre-event promotion of moderator role in all marketing efforts; acknowledgement of company and role within host welcome/close address; opportunity to showcase companies thought leadership and expertise; inclusion in all event summary articles, podcasts, and ebooks.

Post-conference:

- 100 GDPR-approved qualified, full demo, end-user attendee leads. (Includes First Name, Last Name, Title, Department, Company, Address, Email and Phone)
- Inclusion of company logo/link in (3) Evaluating Biopharma event summary articles
- Preferred rate to sponsor Evaluating Biopharma Podcast Series (includes: logo, two company descriptions by podcast moderator)
- Preferred rate to include full page, 4C advertisement(s) in Evaluating Biopharma ebook Series (includes: 20,000 bioprocessing circulation + 50 GDPR lead-gen)
- Preferred rates on CHI marketing opportunities (email blast, webcasts, etc.)
- Preferred rate on dedicated 1:1 targeted attendee calls

Pricing Options

Single Event

Sponsorship Only:	\$8,000
Moderator + Sponsorship Package	\$15,000

Multiple Events

Sponsorship Only:	\$6,500
Moderator + Sponsorship Package	\$12,500

**Online
Interactive Events**

**Ready to Learn More?
Contact Us For More
Information:**

**For General Series
Information**

Brian Caine
Co-Founder and
Managing Director
908-809-0946
bcaine@cambridge
innovationinstitute.com

Companies A-M

Phillip Zakim-Yacouby
Senior Manager, Business
Development
Evaluating Biopharma
Phone: (+1) 617-247-1815
Email: pzakim-yacouby@
cambridgeinnovation
institute.com

Companies N-Z

Aimee Croke
Senior Manager,
Business Development
Evaluating Biopharma
Phone: (+1) 781-292-0777
Email: acroke@cambridge
innovationinstitute.com

The Evaluating Biopharma Podcast Series



Provides the bioprocessing decision makers with convenient opportunity to access our expert's perspective and insight to help facilitate new ideas to improve process efficiency, reduce costs, and accelerate manufacturing and product approval.

Each podcast is single-sponsored and includes:

- In partnership designation
- Company logo
- Two (2) moderator live reads of company's expertise and offering within the podcast

Pricing

Single Podcast

\$1,750

Multiple Podcasts (per)

\$1,500

Podcast Examples



The Evaluating Biopharma eBook Series

Distributed monthly to 20,000 bioprocessing decision makers, Evaluating Biopharma's eBooks provide the industry with a unique opportunity to re-engage with content originally presented at our events.

Each eBook sponsorship includes:

- Your full-page advertisement. Live linked and referenced in the TOC
- 50 GDPR-qualified lead-gen
- Company logo (if also an event sponsor)

Pricing

Single eBook

\$2,500

Multiple eBooks (per)

\$2,000

INQUIRE ABOUT SPONSORSHIP

January 26, 2023
11am-1:30pm ET
Online and Interactive

Common efficacy and quality challenges impact every company's ability to effectively produce and manufacture enough viral vector-based gene therapy products to support clinical and commercial supply demands. Our experts share their personal experiences and insights to help anticipate challenges and implement better CMC strategies to accelerate success.

JANUARY 26, 2023, 11:00 AM - 1:30 PM ET, VIRTUAL

GENE THERAPY ANALYTICS

Implementing Better CMC Strategies

Meeting Agenda (all times ET and subject to change)

Moderator: *Ben Locwin, Executive, Black Diamond Networks*

11:00am – 11:15am: **Welcome + Meet and Greet Networking**

11:15 – 11:40am: **Conversation #1: Potency, Regulatory and Comparability Strategies for Gene Therapies**

Jim Richardson, Senior Director, Analytical Development, Interius Biotherapeutics

- CMC challenges and strategies
- The role of quality in gene therapy development
- Potency assay strategies
- Comparability – recognizing when a change is necessary

11:40 – 12:05pm: **Conversation #2: Identifying and Overcoming Quality Challenges in Gene Therapy**

Susan D'Costa, Chief Technology Officer, Alcyone Therapeutics

- Analysis and characterization
- Development and qualification
- Comparability and product-related impurities
- Stability and formulation
- Impact of post-translational modifications
- Ensuring delivery to the precise target

12:05 – 12:30pm: **Conversation #3: Making Proper CMC Investments to Reduce Risk and Maximize ROI**

Mike Kelly, Senior Vice President, CMC, Atsena Therapeutics

- Starting with a clear strategy: Build to sell or manufacture
- Ensuring CMC investments deliver exactly what regulators want to see
- Scalability considerations to properly transition operations from R&D to clinical
- Building commercially feasible program profile
- Identifying and improving technology platforms and assay designs to support strategy
- Controlling COGs

12:30pm – 1:30pm: Deep Dive Networking

What to expect as an Evaluating Biopharma attendee:

- Unique access to our speakers' thought process, experience, insight
- Roadmap to making better bioprocessing technology and operational decisions
- Interactive forum to meet, interact and learn from industry peers

February 23, 2023
11am-1:30pm ET
Online and Interactive

Better cell culture media, cell lines, and bioreactor strategies are responsible for yielding 10+g/l on a consistent basis. Going forward, companies will continue to implement new technologies and process designs to support emerging therapeutics. Our experts share their personal experiences and insight to help anticipate challenges and chose appropriate technologies to support your production strategies.

CELL CULTURE PROCESS OPTIMIZATION

Improving Upstream Productivity

Meeting Agenda (all times ET and subject to change)

Moderator: *Susan Jones, Chief of Technical Operations, Tourmaline Bio, Inc*

11:00 am – 11:15 am **Welcome + Meet and Greet Networking**

11:15 am – 11:40 am **Conversation #1: Strategy Options to Support mRNA Development and Manufacturing**

Philip Probert, Technology Lead – Biologics, Centre for Process Innovation

- mRNAs potential to treat previously untreatable diseases
- Ensuring consistency and scalability
- Implementing a platform-based approach
- Development strategy considerations

11:40 am – 12:05 pm **Conversation #2: (Re)Evaluating Strategies to Improve Process Efficiency**

Robert Dream, Managing Director, HDR

- Having an inclusive vision of the process
- Designing and implementing a flexible framework
- Evaluating and implementing proper technology and skill
- Emphasizing safety, quality, efficacy and regulatory mandates
- The bottom line – delivering ROI

12:05 – 12:30 pm **Conversation #3: Lessons Learned Scaling-up Cell Culture Processes from Bench to GMP**

- Factors to incorporate in planning scale-up of cell culture processes
- Understanding CHO hosts responses during scale-up
- Strategy preparation to address expected/unexpected responses
- Case study #1: A successful scale-up process – what went right

12:30pm – 1:30pm: **Deep Dive Networking**

What to expect as an Evaluating Biopharma attendee:

- Unique access to our speakers' thought process, experience, insight
- Roadmap to making better bioprocessing technology and operational decisions
- Interactive forum to meet, interact and learn from industry peers

CELL THERAPY ANALYTICS

Overcoming CMC Challenges

April 20, 2023
11am-1:30pm ET
Online and Interactive

The complexity and rapid growth of autologous and allogeneic cell therapies presents significant new CMC challenges companies must address and overcome. Our experts share their personal experiences and insight to help anticipate challenges and implement better CMC strategies to accelerate success.

Meeting Agenda (all times ET and subject to change)

Moderator: *Dominic Clarke, Chief Technology Officer, Cell & Gene Therapies, AllCells, A Discovery Life Sciences Company*

11:00am – 11:15am: Welcome + Meet and Greet Networking

11:15 – 11:40am: Conversation #1: Analytical Challenges for Cell Therapies

- The evolving role analytics plays in understanding comparability, safety and potency
- Catching up to the rapidly changing analytical method options
- The latest analytical techniques and critical selection factors

11:40 – 12:05pm: Conversation #2: Identifying and Overcoming Cell Therapy CMC Challenges

- Ensuring proper comparability following a process change
- Real-time evaluation and interpretation of potency assays
- Ensuring proper quality control processes and procedures

12:05 – 12:30pm: Conversation #3: Cell Banking Solutions for Allogeneic Cell Therapies

- Understanding the unique allogeneic business model
- Implementing a production strategy based on cell bank lifecycle variability
- Balancing regulatory mandates and implications

12:30pm – 1:30pm: Deep Dive Networking

What to expect as an Evaluating Biopharma attendee:

- Unique access to our speakers' thought process, experience, insight
- Roadmap to making better bioprocessing technology and operational decisions
- Interactive forum to meet, interact and learn from industry peers

CELL LINE OPTIMIZATION

Leveraging Technology to Improve
Speed, Quality, Cost

May 25, 2023
11am-1:30pm ET
Online and Interactive

Developing and engineering recombinant protein expression platforms are not for the faint of heart. Many variables must be considered during the development process. When cell line challenges arise, scientists must engineer solutions to overcome. Our experts share their personal experiences and insight to help you identify and overcome today's cell line challenges.

Meeting Agenda (all times ET and subject to change)


- 11:00am – 11:15am: Welcome + Meet and Greet Networking**
- 11:15 – 11:40am: Conversation #1: Identifying CLD Process Improvements to Improve Speed and Flexibility**
- Elizabeth Schneiderman, Scientist, Vaccine Program Production Laboratory, VRC, NIH*
- Media is the key – identifying, understanding, evaluating
 - Technical recommendations to identify alternative feeding strategies
 - Better approaches to reducing cloning timelines
 - Implementing proper technologies to support testing and objectives
- 11:40 – 12:05pm: Conversation #2: Leveraging Technology to Improve Cell Line Stability and Development**
- 12:05 – 12:30pm: Conversation #3: Implementing Novel Approaches to Support Next-Gen Cell Line Development**
- 12:30pm – 1:30pm: Deep Dive Networking**

What to expect as an Evaluating Biopharma attendee:

- Unique access to our speakers' thought process, experience, insight
- Roadmap to making better bioprocessing technology and operational decisions
- Interactive forum to meet, interact and learn from industry peers

PURIFICATION

New Technologies and Strategies to Support
Complex Molecules



June 29, 2023
11am-1:30pm ET
Online and Interactive

Newer and more complex molecules often complicate existing downstream processes. New, innovative technologies are necessary to ensure safe, efficient, and effective capture and purification of emerging modalities. Our experts share their personal experiences and insight to help anticipate challenges and choose appropriate technologies to support your downstream strategies.

Meeting Agenda (all times ET and subject to change)

- 11:00am – 11:15am:** Welcome + Meet and Greet Networking
- 11:15am – 11:40am:** Conversation #1: Purification Strategies to Support New Therapeutic Modalities
- 11:40am – 12:05pm:** Conversation #2: Optimizing Purifications of Challenging Drug Targets
- 12:05pm – 12:30pm:** Conversation #3: Leveraging Transformative Technologies to Overcome Downstream Challenges
- 12:30pm – 1:30pm:** Deep Dive Networking

What to expect as an Evaluating Biopharma attendee:

- Unique access to our speakers' thought process, experience, insight
- Roadmap to making better bioprocessing technology and operational decisions
- Interactive forum to meet, interact and learn from industry peers

2023 Evaluating Biopharma Schedule of Events

Online
Interactive Events

Attendee Feedback

“Thanks for inviting me and for a really good ‘interview’. I was a bit skeptical in the beginning, but you both proved me wrong. Even the follow up “table” discussions were quite inspiring. Congratulations.”

Stefan Schmidt, COO,
BioAtrium

“Networking format is great! I learned a lot from the case studies”

Director, Downstream
Processing

SEPTEMBER 2023 - SMART(ER) BIOMANUFACTURING: EVALUATING THE RISKS AND OPPORTUNITIES

Advances in manufacturing 4.0 including digitalization, AI, and machine learning offer biopharmaceutical company's unique opportunities to overhaul antiquated processes to increase productivity, flexibility, and reduced cost. However, as with each great innovation, there are risks, uncertainties, and challenges. Our experts share their individual experiences and insight to help you anticipate challenges and implement better manufacturing strategies to accelerate success.

Case Study #1: Connecting Technology, Culture, and Strategy to Support Success

Case Study #2: Focusing on the Facility – Structure, Digitalization, Processes

Case Study #3: Harnessing Data and Digital Technologies to Accelerate Manufacturing Efficiencies

OCTOBER 2023 - CONTINUOUS BIOPROCESSING

With competition heating up, companies are now looking at cost savings. Process intensification and optimization via continuous processing fills this urgent need. However, despite the promise of increased productivity, the industry is still slow to adopt continuous processing at clinical or manufacturing scale. Our experts share their personal experiences and insight to help you anticipate challenges and implement better continuous/optimization strategies to accelerate success.

Case Study #1: Why a Truly Continuous Downstream Process Has Been So Elusive

Case Study #2: The Path to Continuous Starts with an Intensification Strategy

Case Study #3: Labor Challenges and Considerations When Implementing a Continuous Process

NOVEMBER 2023 - ACCELERATING ANALYTICAL DEVELOPMENT: OPTIMIZING BIOTHERAPEUTIC DEVELOPMENT EFFICIENCY

Today's analytical groups are facing increased pressure to deliver key studies faster than ever before – and at lower costs. Scientists must evaluate best practices, exchange ideas, integrate new technologies to improve and accelerate existing analytical methods to support business goals. Our experts share their personal experiences and insight to help you overcome existing challenges and implement better strategies.

Case Study #1: How to Reduce Analytical Lifecycle Steps to Improve Product Development

Case Study #2: Implementing PAT Advances to Transition to Digital Manufacturing

Case Study #3: Identifying Opportunities and Challenges in Analytical Method Lifecycle Management

DECEMBER 2023 - CELL THERAPY MANUFACTURING: AUTOLOGOUS VS. ALLOGENEIC STRATEGIES

While related, scaling autologous and allogeneic cell therapies require vastly different manufacturing approaches, equipment, and technologies. Regardless of the platform chosen, implementing the right strategy early is the key to success. Our experts share their personal experiences and insight to help you anticipate challenges and implement better cell therapy strategies.

Case Study #1: Selecting the Right Technologies and Equipment to Support Your Cell Therapy Strategy

Case Study #2: Identifying Cost Savings to Improve Autologous Manufacturing Efficiency

Case Study #3: Keys to Implementing the Right Manufacturing Strategy

“This is a very interesting forum. Great to hear all the perspectives and also really enjoyed the connections. I have been chatting with other folks, so I would say it has been a useful experience”